Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has scheduled its third quarter 2024 financial results announcement for November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial performance and provide a corporate update. The webcast will be accessible through Liquidia's website and will remain archived for one year.
Liquidia (NASDAQ: LQDA), una compagnia biofarmaceutica focalizzata sulle terapie per malattie cardiopolmonari rare, ha programmato l'annuncio dei suoi risultati finanziari del terzo trimestre 2024 per l'11 novembre 2024. L'azienda ospiterà un webcast dal vivo alle 8:30 ora orientale per discutere le performance finanziarie e fornire un aggiornamento aziendale. Il webcast sarà accessibile attraverso il sito web di Liquidia e rimarrà archiviato per un anno.
Liquidia (NASDAQ: LQDA), una compañía biofarmacéutica enfocada en terapias para enfermedades cardiopulmonares raras, ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el 11 de noviembre de 2024. La empresa llevará a cabo una transmisión en vivo a las 8:30 a.m. hora del Este para discutir el rendimiento financiero y proporcionar una actualización corporativa. La transmisión estará accesible a través del sitio web de Liquidia y se mantendrá archivada durante un año.
Liquidia (NASDAQ: LQDA), 희귀 심폐 질환 치료에 주력하는 생물의약품 회사가 2024년 3분기 재무 실적 발표를 2024년 11월 11일로 예정했습니다. 회사는 동부 표준시 기준 오전 8시 30분에 재무 성과와 기업 업데이트에 대해 논의하는 라이브 웹캐스트를 진행할 것입니다. 이 웹캐스트는 Liquidia의 웹사이트를 통해 접근 가능하며 1년 동안 아카이브됩니다.
Liquidia (NASDAQ: LQDA), une entreprise biopharmaceutique axée sur les thérapies des maladies cardiopulmonaires rares, a prévu d'annoncer ses résultats financiers pour le troisième trimestre 2024 le 11 novembre 2024. L'entreprise organisera un webinaire en direct à 8h30, heure de l'Est, pour discuter de sa performance financière et fournir une mise à jour sur l'entreprise. Le webinaire sera accessible via le site Internet de Liquidia et restera archivé pendant un an.
Liquidia (NASDAQ: LQDA), ein biopharmazeutisches Unternehmen, das sich auf Therapien für seltene kardiopulmonale Erkrankungen konzentriert, hat die Bekanntgabe seiner Finanzergebnisse für das dritte Quartal 2024 für den 11. November 2024 angesetzt. Das Unternehmen wird um 8:30 Uhr østlicher Zeit ein Live-Webcast veranstalten, um die finanzielle Leistung zu erörtern und ein Unternehmensupdate bereitzustellen. Der Webcast wird über die Website von Liquidia zugänglich sein und ein Jahr lang archiviert bleiben.
- None.
- None.
MORRISVILLE, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2024 financial results on Monday, November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
When will Liquidia (LQDA) release Q3 2024 earnings?
What time is Liquidia's (LQDA) Q3 2024 earnings call?
How can I access Liquidia's (LQDA) Q3 2024 earnings webcast?
